Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia

G. Barosi, L. N. Liberato, A. Costa, E. Ascari

Research output: Contribution to journalArticle

45 Citations (Scopus)

Abstract

In an attempt to reduce myeloproliferation, we administered recombinant α-2b interferon (r-αINF) to ten patients with myelofibrosis with myeloid metaplasia (MMM) in a hypercellular phase, as part of a phase II trial. Two patients experienced severe side effects and stopped treatment before completion of the first week. In the eight evaluable patients, r-αINF was given for 16 weeks at an initial dosage of 3×106 U/day, with monthly increments in the case of response failure, i.e. a decrease in WBC or platelet count of less than 25% of the initial value. Two cases responded at the starting dosage, while the effective dosage was 5×106 U/day in the others. At the end of the 16th week, Hb showed minor changes: from an initial value of 12.08 g/dl, range 8.3-17.3, to 11.6 g/dl, range 7.7-18 (P=0.12); WBC were reduced from 54×109/l, range 6.4-69.4, to 17.5×109/l, range 5-39 (P=0.09, 4/8 responses); platelets decreased from 775×109/l, range 215-1748, to 403×109/l, range 118-730 (P=0.008, 8/8 responses). Minor changes in spleen size were also noted, while no significant changes in bone marrow fibrosis occurred. Influenza-like symptoms and fatigue were common side effects. In conclusion, r-αINF has a role as a non-leukemogenic cytoreductive agent in the therapy of MMM, especially for cases with thrombocytosis.

Original languageEnglish
Pages (from-to)271-274
Number of pages4
JournalBlut
Volume58
Issue number6
DOIs
Publication statusPublished - Jun 1989

Fingerprint

Primary Myelofibrosis
Interferon-alpha
Interferons
Thrombocytosis
Platelet Count
Human Influenza
Fatigue
Blood Platelets
Spleen
Therapeutics

Keywords

  • Cytoreduction
  • Myelofibrosis with myeloid metaplasia
  • Recombinant alpha-interferon

ASJC Scopus subject areas

  • Hematology

Cite this

Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia. / Barosi, G.; Liberato, L. N.; Costa, A.; Ascari, E.

In: Blut, Vol. 58, No. 6, 06.1989, p. 271-274.

Research output: Contribution to journalArticle

Barosi, G. ; Liberato, L. N. ; Costa, A. ; Ascari, E. / Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia. In: Blut. 1989 ; Vol. 58, No. 6. pp. 271-274.
@article{b18d686dfbf341d788861be681850b44,
title = "Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia",
abstract = "In an attempt to reduce myeloproliferation, we administered recombinant α-2b interferon (r-αINF) to ten patients with myelofibrosis with myeloid metaplasia (MMM) in a hypercellular phase, as part of a phase II trial. Two patients experienced severe side effects and stopped treatment before completion of the first week. In the eight evaluable patients, r-αINF was given for 16 weeks at an initial dosage of 3×106 U/day, with monthly increments in the case of response failure, i.e. a decrease in WBC or platelet count of less than 25{\%} of the initial value. Two cases responded at the starting dosage, while the effective dosage was 5×106 U/day in the others. At the end of the 16th week, Hb showed minor changes: from an initial value of 12.08 g/dl, range 8.3-17.3, to 11.6 g/dl, range 7.7-18 (P=0.12); WBC were reduced from 54×109/l, range 6.4-69.4, to 17.5×109/l, range 5-39 (P=0.09, 4/8 responses); platelets decreased from 775×109/l, range 215-1748, to 403×109/l, range 118-730 (P=0.008, 8/8 responses). Minor changes in spleen size were also noted, while no significant changes in bone marrow fibrosis occurred. Influenza-like symptoms and fatigue were common side effects. In conclusion, r-αINF has a role as a non-leukemogenic cytoreductive agent in the therapy of MMM, especially for cases with thrombocytosis.",
keywords = "Cytoreduction, Myelofibrosis with myeloid metaplasia, Recombinant alpha-interferon",
author = "G. Barosi and Liberato, {L. N.} and A. Costa and E. Ascari",
year = "1989",
month = "6",
doi = "10.1007/BF00320164",
language = "English",
volume = "58",
pages = "271--274",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",
number = "6",

}

TY - JOUR

T1 - Cytoreductive effect of recombinant alpha interferon in patients with myelofibrosis with myeloid metaplasia

AU - Barosi, G.

AU - Liberato, L. N.

AU - Costa, A.

AU - Ascari, E.

PY - 1989/6

Y1 - 1989/6

N2 - In an attempt to reduce myeloproliferation, we administered recombinant α-2b interferon (r-αINF) to ten patients with myelofibrosis with myeloid metaplasia (MMM) in a hypercellular phase, as part of a phase II trial. Two patients experienced severe side effects and stopped treatment before completion of the first week. In the eight evaluable patients, r-αINF was given for 16 weeks at an initial dosage of 3×106 U/day, with monthly increments in the case of response failure, i.e. a decrease in WBC or platelet count of less than 25% of the initial value. Two cases responded at the starting dosage, while the effective dosage was 5×106 U/day in the others. At the end of the 16th week, Hb showed minor changes: from an initial value of 12.08 g/dl, range 8.3-17.3, to 11.6 g/dl, range 7.7-18 (P=0.12); WBC were reduced from 54×109/l, range 6.4-69.4, to 17.5×109/l, range 5-39 (P=0.09, 4/8 responses); platelets decreased from 775×109/l, range 215-1748, to 403×109/l, range 118-730 (P=0.008, 8/8 responses). Minor changes in spleen size were also noted, while no significant changes in bone marrow fibrosis occurred. Influenza-like symptoms and fatigue were common side effects. In conclusion, r-αINF has a role as a non-leukemogenic cytoreductive agent in the therapy of MMM, especially for cases with thrombocytosis.

AB - In an attempt to reduce myeloproliferation, we administered recombinant α-2b interferon (r-αINF) to ten patients with myelofibrosis with myeloid metaplasia (MMM) in a hypercellular phase, as part of a phase II trial. Two patients experienced severe side effects and stopped treatment before completion of the first week. In the eight evaluable patients, r-αINF was given for 16 weeks at an initial dosage of 3×106 U/day, with monthly increments in the case of response failure, i.e. a decrease in WBC or platelet count of less than 25% of the initial value. Two cases responded at the starting dosage, while the effective dosage was 5×106 U/day in the others. At the end of the 16th week, Hb showed minor changes: from an initial value of 12.08 g/dl, range 8.3-17.3, to 11.6 g/dl, range 7.7-18 (P=0.12); WBC were reduced from 54×109/l, range 6.4-69.4, to 17.5×109/l, range 5-39 (P=0.09, 4/8 responses); platelets decreased from 775×109/l, range 215-1748, to 403×109/l, range 118-730 (P=0.008, 8/8 responses). Minor changes in spleen size were also noted, while no significant changes in bone marrow fibrosis occurred. Influenza-like symptoms and fatigue were common side effects. In conclusion, r-αINF has a role as a non-leukemogenic cytoreductive agent in the therapy of MMM, especially for cases with thrombocytosis.

KW - Cytoreduction

KW - Myelofibrosis with myeloid metaplasia

KW - Recombinant alpha-interferon

UR - http://www.scopus.com/inward/record.url?scp=0024324629&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024324629&partnerID=8YFLogxK

U2 - 10.1007/BF00320164

DO - 10.1007/BF00320164

M3 - Article

VL - 58

SP - 271

EP - 274

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

IS - 6

ER -